Study Completed

CE in MRI: Liver

Bayer Identifier:

13358

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2008-006966-27

EU CT Number:

Not Available

Primovist: DDI with OATP-Inhibitor

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

18 Years

Trial summary

Enrollment Goal

Trial Dates

May 2009 - July 2009

Phase

Phase 1

Could I Receive a placebo

N/A

Products

Eovist/Primovist (Gadoxetate disodium, BAY86-4873)

Accepts Healthy Volunteer

N/A

Where to participate

Status	Institution	Location
Completed	Bayer Schering Pharma AG	Berlin, 13353, Germany

Trial design

Open-label, randomized, single-center, crossover study to evaluate the possible influence of erythromycin as a representative of an inhibitor of the organic anion transporting peptide on the hepatocyte uptake of Eovist/Primovist in liver MR imaging in healthy volunteers

Trial Type

Interventional

Intervention Type

N/A

Trial Purpose

N/A

Allocation

N/A

Blinding

N/A

Assignment

N/A

Trial Arms

N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.